113 related articles for article (PubMed ID: 34949032)
1. The Challenge of Sustainability of High-Cost Oncological Drugs: A Budgeting Model in an Italian Cancer Center.
Masini C; Gallegati D; Gentili N; Massa I; Ciucci R; Altini M
Int J Environ Res Public Health; 2021 Dec; 18(24):. PubMed ID: 34949032
[TBL] [Abstract][Full Text] [Related]
2. The role of clinical trials in the sustainability of the Italian national health service cancer drug expenditure.
Gasperoni L; Cafaro A; Ferretti E; Di Iorio V; Nanni O; Masini C
Eur J Hosp Pharm; 2023 Mar; 30(2):96-100. PubMed ID: 35577545
[TBL] [Abstract][Full Text] [Related]
3. Erratum: Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection.
J Vis Exp; 2020 Sep; (163):. PubMed ID: 32986035
[TBL] [Abstract][Full Text] [Related]
4. Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.2013.50.8267. [Epub 2014 Mar 31].
Trump D
Urol Oncol; 2016 May; 34(5):251. PubMed ID: 25937427
[TBL] [Abstract][Full Text] [Related]
5. Challenges to achieving value in drug spending in a decentralized country: the Spanish case.
Antoñanzas F
Value Health; 2003; 6 Suppl 1():S52-63. PubMed ID: 12846926
[TBL] [Abstract][Full Text] [Related]
6. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
7. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany.
Schwermann T; Greiner W; v d Schulenburg JM
Value Health; 2003; 6 Suppl 1():S20-30. PubMed ID: 12846923
[TBL] [Abstract][Full Text] [Related]
8. Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
L'Abbate A; Tolomeo D; Cifola I; Severgnini M; Turchiano A; Augello B; Squeo G; D'Addabbo P; Traversa D; Daniele G; Lonoce A; Pafundi M; Carella M; Palumbo O; Dolnik A; Muehlematter D; Schoumans J; Van Roy N; De Bellis G; Martinelli G; Merla G; Bullinger L; Haferlach C; Storlazzi CT
Leukemia; 2018 Oct; 32(10):2304. PubMed ID: 29985446
[TBL] [Abstract][Full Text] [Related]
9. The Comprehensive Cancer Care Network of Romagna: the opportunities generated by the OECI accreditation program.
Ancarani V; Bernabini M; Zani C; Altini M; Amadori D
Tumori; 2015; 101 Suppl 1():S55-9. PubMed ID: 27096275
[TBL] [Abstract][Full Text] [Related]
10. Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study.
Maltoni R; Balzi W; Rossi T; Fabbri F; Bravaccini S; Montella MT; Massa I; Bertoni L; Falcini F; Altini M
Curr Oncol; 2022 Jan; 29(2):433-438. PubMed ID: 35200539
[TBL] [Abstract][Full Text] [Related]
11. Proportion of Thick versus Thin Melanomas as a Benchmarking Tool.
Pagliarello C; Magi S; Mazzoni L; Stanganelli I
J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884250
[TBL] [Abstract][Full Text] [Related]
12. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
13. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
14. Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe.
Mills M; Kanavos P
Health Policy; 2020 Mar; 124(3):239-251. PubMed ID: 31926651
[TBL] [Abstract][Full Text] [Related]
15. The Economic Impact of Clinical Research in an Italian Public Hospital: The Malignant Pleural Mesothelioma Case Study.
Ippoliti R; Falavigna G; Grosso F; Maconi A; Randi L; Numico G
Int J Health Policy Manag; 2018 Aug; 7(8):728-737. PubMed ID: 30078293
[TBL] [Abstract][Full Text] [Related]
16. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
Schey C; Milanova T; Hutchings A
Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
[TBL] [Abstract][Full Text] [Related]
17. Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience.
Grocott R
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):181-7. PubMed ID: 19402806
[TBL] [Abstract][Full Text] [Related]
18. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in Italy.
Capri S; Migliore A; Loconsole F; Barbieri M
J Med Econ; 2020 Apr; 23(4):353-361. PubMed ID: 31856609
[No Abstract] [Full Text] [Related]
20. Italian Public Health Expenditure for Vitamin D is still high: New Outlook to Saving From a Consumption Analysis in the Liguria Region.
Moretti M; Paleari L; Figallo F; Garbarini C; Ponti E; Schena F; Marinelli L
Clin Ther; 2021 Nov; 43(11):1969-1982. PubMed ID: 34756467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
